Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.46 billion. The enterprise value is $1.51 billion.
| Market Cap | 1.46B |
| Enterprise Value | 1.51B |
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 40.09 million shares outstanding. The number of shares has decreased by -8.52% in one year.
| Current Share Class | 40.09M |
| Shares Outstanding | 40.09M |
| Shares Change (YoY) | -8.52% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 1.77% |
| Owned by Institutions (%) | 109.28% |
| Float | 39.37M |
Valuation Ratios
The trailing PE ratio is 39.94 and the forward PE ratio is 11.03. PCRX's PEG ratio is 1.10.
| PE Ratio | 39.94 |
| Forward PE | 11.03 |
| PS Ratio | 1.97 |
| Forward PS | 1.89 |
| PB Ratio | 2.04 |
| P/TBV Ratio | 3.48 |
| P/FCF Ratio | 8.65 |
| P/OCF Ratio | 8.26 |
| PEG Ratio | 1.10 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.73, with an EV/FCF ratio of 8.91.
| EV / Earnings | 39.93 |
| EV / Sales | 2.03 |
| EV / EBITDA | 12.73 |
| EV / EBIT | 50.69 |
| EV / FCF | 8.91 |
Financial Position
The company has a current ratio of 4.68, with a Debt / Equity ratio of 0.48.
| Current Ratio | 4.68 |
| Quick Ratio | 3.38 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 2.56 |
| Debt / FCF | 2.01 |
| Interest Coverage | 2.11 |
Financial Efficiency
Return on equity (ROE) is 5.24% and return on invested capital (ROIC) is 3.74%.
| Return on Equity (ROE) | 5.24% |
| Return on Assets (ROA) | 1.49% |
| Return on Invested Capital (ROIC) | 3.74% |
| Return on Capital Employed (ROCE) | 2.76% |
| Weighted Average Cost of Capital (WACC) | 5.04% |
| Revenue Per Employee | $896,624 |
| Profits Per Employee | $45,509 |
| Employee Count | 829 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.15 |
Taxes
| Income Tax | -789,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +52.81% in the last 52 weeks. The beta is 0.22, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +52.81% |
| 50-Day Moving Average | 31.19 |
| 200-Day Moving Average | 25.66 |
| Relative Strength Index (RSI) | 82.71 |
| Average Volume (20 Days) | 1,032,334 |
Short Selling Information
The latest short interest is 3.35 million, so 8.35% of the outstanding shares have been sold short.
| Short Interest | 3.35M |
| Short Previous Month | 4.26M |
| Short % of Shares Out | 8.35% |
| Short % of Float | 8.50% |
| Short Ratio (days to cover) | 1.39 |
Income Statement
In the last 12 months, PCRX had revenue of $743.30 million and earned $37.73 million in profits. Earnings per share was $0.91.
| Revenue | 743.30M |
| Gross Profit | 578.69M |
| Operating Income | 29.72M |
| Pretax Income | 36.94M |
| Net Income | 37.73M |
| EBITDA | 118.37M |
| EBIT | 29.72M |
| Earnings Per Share (EPS) | $0.91 |
Balance Sheet
The company has $295.58 million in cash and $340.28 million in debt, with a net cash position of -$44.70 million or -$1.11 per share.
| Cash & Cash Equivalents | 295.58M |
| Total Debt | 340.28M |
| Net Cash | -44.70M |
| Net Cash Per Share | -$1.11 |
| Equity (Book Value) | 712.32M |
| Book Value Per Share | 17.85 |
| Working Capital | 464.13M |
Cash Flow
In the last 12 months, operating cash flow was $176.90 million and capital expenditures -$7.90 million, giving a free cash flow of $169.00 million.
| Operating Cash Flow | 176.90M |
| Capital Expenditures | -7.90M |
| Depreciation & Amortization | 88.65M |
| Net Borrowing | -85.00M |
| Free Cash Flow | 169.00M |
| FCF Per Share | $4.21 |
Margins
Gross margin is 77.85%, with operating and profit margins of 4.00% and 5.08%.
| Gross Margin | 77.85% |
| Operating Margin | 4.00% |
| Pretax Margin | 4.97% |
| Profit Margin | 5.08% |
| EBITDA Margin | 15.92% |
| EBIT Margin | 4.00% |
| FCF Margin | 22.74% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 8.52% |
| Shareholder Yield | 8.52% |
| Earnings Yield | 2.50% |
| FCF Yield | 11.56% |
Analyst Forecast
The average price target for PCRX is $33.57, which is -7.93% lower than the current price. The consensus rating is "Hold".
| Price Target | $33.57 |
| Price Target Difference | -7.93% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 6.74% |
| EPS Growth Forecast (3Y) | 18.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 2.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 6 |